SCHEMBL4472512

SCHEMBL4472512

CCCCN(CCC)C(=O)Cc1c(C(=O)C(C)(C)C)sc2ccc(OC)cc12

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TSPO P30536 2/20 0.36
CYP1A2 P05177 1/20 0.36
CYP3A4 P08684 1/20 0.36
CYP2D6 P10635 1/20 0.36
CYP2C19 P33261 1/20 0.36
KDM4E B2RXH2 2/20 0.36
NPC1 O15118 2/20 0.36
ALDH1A1 P00352 2/20 0.36
LMNA P02545 2/20 0.36
HPGD P15428 2/20 0.36
RAB9A P51151 2/20 0.36
GLA P06280 1/20 0.36
GAA P10253 1/20 0.36
ICAM1 P05362 2/20 0.36
SELE P16581 2/20 0.36
VCAM1 P19320 1/20 0.36
MTNR1A P48039 1/20 0.36
PTGS2 P35354 1/20 0.36
CNR2 P34972 1/20 0.35
PKM P14618 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4187170 0.98 CYP1A2 (0.38) CYP1A2CYP3A4CYP2D6CYP2C19KDM4E
SCHEMBL4479968 0.96 TSPO (0.39) TSPOKDM4ENPC1ALDH1A1RAB9A
SCHEMBL4188725 0.94 CYP1A2 (0.43) CYP1A2CYP3A4CYP2D6CYP2C19KDM4E
SCHEMBL4193966 0.87 POLB (0.43) TSPOCYP1A2CYP3A4CYP2C19KDM4E
SCHEMBL4193967 0.87 MLYCD (0.38) KDM4EALDH1A1ICAM1SELEVCAM1
SCHEMBL4478135 0.85 ICAM1 (0.41) KDM4ENPC1ALDH1A1LMNARAB9A
SCHEMBL4191256 0.85 KDM4E (0.41) TSPOCYP1A2CYP3A4CYP2C19KDM4E
SCHEMBL4189808 0.84 KDM4E (0.41) TSPOCYP1A2CYP3A4CYP2C19KDM4E
SCHEMBL4191228 0.84 PTGS2 (0.39) TSPOKDM4ENPC1ALDH1A1LMNA
SCHEMBL13762171 0.84 ALDH1A1 (0.35) TSPOCYP1A2CYP3A4CYP2C19KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7576122-B2 Ophthalmic compositions for treating ocular hypertension MERCK & CO. INC. (US) 2009-08-18 US claimed
US-20060276504-A1 Ophthalmic compositions for treating ocular hypertension MERCK SHARP & DOHME CORP. 2006-12-07 US claimed
US-7576122-B2 Ophthalmic compositions for treating ocular hypertension MERCK & CO. INC. (US) 2009-08-18 US disclosed
US-20080287489-A1 Ophthalmic compositions for treating ocular hypertension MERCK SHARP & DOHME CORP. 2008-11-20 US disclosed
US-20060276504-A1 Ophthalmic compositions for treating ocular hypertension MERCK SHARP & DOHME CORP. 2006-12-07 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060276504-A1 Ophthalmic compositions for treating ocular hypertension KCNH2, KCNJ11, KCNN1 TSPO 936/4885CYP1A2 2713/4885CYP3A4 3953/4885
US-20080287489-A1 Ophthalmic compositions for treating ocular hypertension KCNH2, KCNH3, KCNJ11 TSPO 1132/4885CYP1A2 2253/4885CYP3A4 3932/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.